1. Home
  2. AEC vs LUNG Comparison

AEC vs LUNG Comparison

Compare AEC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEC

Anfield Energy Inc.

HOLD

Current Price

$2.38

Market Cap

82.0M

Sector

Real Estate

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$2.77

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AEC
LUNG
Founded
1989
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.0M
97.1M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
AEC
LUNG
Price
$2.38
$2.77
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $4.25
AVG Volume (30 Days)
40.6K
★ 1.3M
Earning Date
05-01-2015
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.64
EPS
★ N/A
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.39
Revenue Next Year
$48.15
$8.68
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$2.31
$1.13
52 Week High
$10.24
$3.25

Technical Indicators

Market Signals
Indicator
AEC
LUNG
Relative Strength Index (RSI) 24.12 N/A
Support Level N/A N/A
Resistance Level $3.18 N/A
Average True Range (ATR) 0.19 0.00
MACD -0.04 0.00
Stochastic Oscillator 7.91 0.00

Price Performance

Historical Comparison
AEC
LUNG

About AEC Anfield Energy Inc.

Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: